Current Happenings

Robin K. Ohls, MD


rko photo-1.jpg
  Robin K. Ohls, MD

The American Academy of Pediatrics
recently published a study headed by Dr. Robin Ohls​, an E.W. “Al” Thrasher award recipient, from the University of New Mexico entitled, “A Randomized, Masked, Placebo-Controlled Study of Darbepoetin Alfa in Preterm Infants.” When administered every 1 to 3 weeks in anemic adults, darbepoetin alfa (Darbe) increases hematocrit by stimulating red blood cell production. Ohls’ study assessed weekly dosing of Darbe in preterm infants as compared to erythropoietin (Epo) or placebo, the effects of which were previously unknown. Results from the study indicated that infants receiving Darbe or Epo required fewer blood transfusions, were exposed to fewer donors, and had higher hematocrit levels than the placebo group. Additionally, infants in the Darbe group required less-frequent dosing than those in the Epo group. These results suggest that Darbe and Epo can reduce or eliminate the need for transfusions in preterm infants.

 ​Please follow this link for the article: 
View All

Posts by Category